Studies in GEM models with different genetic backgrounds invariably show that ERG overexpression, which recapitulates the TMPRSS2-ERG fusion in patients, is insufficient to drive prostate oncogenesis in mice until very advanced age (>24 months)25,28–31. The gene discussed is TMPRSS2; the disease is medical procedure.